NOAKs bei Patienten mit KHK: Wann ist eine Gerinnungsanalytik sinnvoll?

Nicht Vitamin-K-antagonistische orale Antikoagulanzien (NOAKs) haben gegenüber Vitamin-K-Antagonisten den Vorteil, dass ihre antithrombotische Aktivität unter Routinebedingungen nicht überwacht werden muss. Dieser Beitrag enthält neben einem Update zum aktuellen Einsatz der NOAKs bei KHK vor allem einen Überblick über die Möglichkeiten der Gerinnungsanalytik bei NOAK-behandelten Patienten.

Schlüsselwörter

NOAK - KHK - Antikoagulation - Gerinnungsanalytik - Anti-Faktor-Xa-Aktivität

• Literatur

• 1 Merlini PA, Bauer KA, Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
• 2 Andreotti F, Testa L, Biondi-Zoccai GGL. et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25.307 patients. Eur Heart J 2006; 27: 519-526
• 3 Rothberg MB, Celestin C, Fiore LD. et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250
• 4 Alexander JH, Lopes RD, James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708
• 5 Oldgren J, Budaj A, Granger CB. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789
• 6 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012; 366: 9-19
• 7 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 38: 2893-2962
• 8 Lip GYH, Windecker S, Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179
• 9 Karjalainen PP, Porela P, Ylitalo A. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732
• 10 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-260
• 11 Paikin JS, Wright DS, Crowther MA. et al. Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. Circulation 2010; 121: 2067-2070
• 12 Dewilde WJ, Oirbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
• 13 Fiedler KA, Maeng M, Mehilli J. et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65: 1619-1629
• 14 Gibson CM, Mehran R, Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423-2434
• 15 Cannon CP, Bhatt DL, Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513-1524
• 16 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330
• 17 Gosselin RC, Gosselin R, Douxfils J. et al. Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS). Hamostaseologie 2017; 37: 4
• 18 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2018; 118: 437-450
• 19 Douxfils J, Ageno W, Samama CM. et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16: 209-219
• 20 Hawes EM, Deal AM, Funk-Adcock D. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-1502